PDCD1 and cancer: Indeed, previous studies indicated that the inhibition of PD-1 promotes an effective immune response against cancer cells (1–5) and targeting PD-L1 or PD-1 using monoclonal antibody blocking PD-1 or PD-L1 has been associated with significant clinical response in a wide range of malignancies (7, 8).